T1	Participants 380 418	patients with recurrent gastric cancer
T2	Participants 482 722	1) Intradermal group (ID Group), 42 patients given an intradermal injections of OK-432. 2) Intramuscular group (IM Group), 40 patients given an intramuscular injections of OK-432. 3) Control group (C Group), 39 patients not given injections
#1	AnnotatorNotes T2	Total of 121 participants.
